Tong Yin, Director of Clinical Diagnostics, Scientific Affairs, Global Oncology Diagnostics at AstraZeneca, shared a post on LinkedIn:
“AstraZeneca Global Diagnostics team is pleased to announce our upcoming ECP ‘Advancing breast cancer diagnostics: Emerging biomarkers, technologies, and testing challenges’ symposium.
Leaders in the pathology field will discuss the evolving landscape of precision medicine in metastatic breast cancer diagnostics, including how to overcome challenges in detecting ESR1 mutations and PTEN deficiency.
If you are attending the congress, please join us on 8th September from 13:00-14:30 CET – we look forward to seeing you there!
Intended for HCPs only.”
More posts fraturing AstraZeneca on OncoDaily.